The bivalent HPV16/18 vaccine is immunogenic and well-tolerated in patients with juvenile idiopathic arthritis (JIA), according to a new study. All but one of the patients (n = 68) and all the controls (n = 55) were seropositive after 12 months. Although HPV-specific antibody concentrations were lower in patients with JIA, this difference was not statistically significant. Moreover, the prevalence of adverse effects was comparable between the two groups, and vaccination was not associated with increased JIA disease activity.